Hepatic real-world outcomes with obeticholic acid in primary biliary cholangitis (HEROES): A trial emulation study design.

Saved in:
Bibliographic Details
Title: Hepatic real-world outcomes with obeticholic acid in primary biliary cholangitis (HEROES): A trial emulation study design.
Authors: Brookhart MA; Department of Population Health Sciences, Duke University, Durham, North Carolina, USA.; Target RWE, Durham, North Carolina, USA., Mayne TJ; Intercept Pharmaceuticals, Morristown, New Jersey, USA., Coombs C; Real World Evidence, Syneos Health, North Carolina, USA., Breskin A; Target RWE, Durham, North Carolina, USA., Ness E; Intercept Pharmaceuticals, Morristown, New Jersey, USA., Bessonova L; Intercept Pharmaceuticals, Morristown, New Jersey, USA., Chu YJ; Intercept Pharmaceuticals, Morristown, New Jersey, USA., Li J; Intercept Pharmaceuticals, Morristown, New Jersey, USA., Fried MW; Target RWE, Durham, North Carolina, USA., Hansen BE; Department of Epidemiology and Biostatistics, Erasmus MC, Rotterdam, The Netherlands.; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.; Toronto Centre for Liver Disease and TGHRI, University Health Network, Toronto, Ontario, Canada., Kowdley KV; Liver Institute Northwest and Elson S. Floyd College of Medicine, Washington State University, Seattle, Washington, USA., Jones D; Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK., Mells G; Department of Hepatology, Cambridge Liver Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.; Academic Department of Medical Genetics, University of Cambridge, Cambridge, UK., Trivedi PJ; Department of Immunology and Immunotherapy, National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre, Centre for Liver and Gastrointestinal Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Hiu S; Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK., Kareithi DN; Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK., Wason J; Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK., Smith R; Department of Hepatology, Cambridge Liver Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Seeger JD; Optum Epidemiology, Boston, Massachusetts, USA., Hirschfield GM; Toronto Centre for Liver Disease and TGHRI, University Health Network, Toronto, Ontario, Canada.
Source: Hepatology (Baltimore, Md.) [Hepatology] 2025 Jun 01; Vol. 81 (6), pp. 1647-1659. Date of Electronic Publication: 2025 Jan 03.
Publication Type: Journal Article; Pragmatic Clinical Trial
Journal Info: Publisher: Wolters Kluwer Health, Inc Country of Publication: United States NLM ID: 8302946 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-3350 (Electronic) Linking ISSN: 02709139 NLM ISO Abbreviation: Hepatology Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1527-3350
DOI:10.1097/HEP.0000000000001174